Otonomy Inc. (Nasdaq: OTIC) reported upbeat results from its AVERTS-2 Phase 3 clinical trial of OTIVIDEX to treat Meniere's disease. Shares of the biopharmaceutical leaped $2.33 to close at $5.12.
Upbeat trial results for Otonomy
November 09, 2017 at 16:23 PM EST
